Top Page
Tonix Pharma
(NASDAQ:TNXP)
Tonix Pharma (TNXP) vs. S&P 500 (SPY)
Tonix Pharma Business Overview & Revenue Model
Tonix Pharma Financial Statement Overview
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 10.09M | 7.77M | 0.00 | 0.00 | 0.00 | Gross Profit |
| 2.33M | 3.03M | -112.09M | -92.31M | -50.51M | EBIT |
| -136.70M | -118.38M | -112.09M | -92.31M | -50.51M | EBITDA |
| -71.73M | -114.09M | -110.84M | -92.26M | -50.48M | Net Income Common Stockholders |
| -130.04M | -116.66M | -116.88M | -92.29M | -52.17M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 98.78M | 24.95M | 120.23M | 178.66M | 77.07M | Total Assets |
| 162.89M | 154.46M | 225.69M | 240.90M | 98.18M | Total Debt |
| 8.12M | 9.81M | 760.00K | 956.00K | 1.31M | Net Debt |
| -90.66M | -15.13M | -119.47M | -177.70M | -75.76M | Total Liabilities |
| 23.33M | 48.93M | 18.51M | 22.18M | 10.54M | Stockholders Equity |
| 139.56M | 105.53M | 207.18M | 218.72M | 87.65M |
| Cash Flow | Free Cash Flow | |||
| -61.05M | -109.90M | -146.20M | -110.86M | -57.13M | Operating Cash Flow |
| -60.92M | -102.00M | -98.05M | -75.56M | -48.57M | Investing Cash Flow |
| -120.00K | -29.07M | -48.15M | -35.31M | -8.56M | Financing Cash Flow |
| 134.87M | 36.52M | 87.84M | 212.49M | 123.11M |
Tonix Pharma Technical Analysis
Tonix Pharma Risk Analysis
Tonix Pharma Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $5.22B | 3.55 | -44.39% | 2.82% | 15.40% | -0.09% | |
52 Neutral | $118.21M | 5.55 | 0.51% | ― | -34.58% | -62.19% | |
51 Neutral | $108.11M | ― | -58.55% | ― | 825.97% | 38.32% | |
50 Neutral | $131.99M | ― | -91.44% | ― | -2.04% | -478.87% | |
48 Neutral | $133.03M | ― | -189.46% | ― | -3.24% | 31.00% | |
43 Neutral | $128.91M | ― | -140.82% | ― | -48.37% | -44.70% | |
34 Underperform | $89.73M | ― | -44.50% | ― | ― | 52.54% |
Tonix Pharma Corporate Events
On May 14, 2025, Tonix Pharmaceuticals announced the appointment of Joseph Hand as General Counsel and Executive Vice President of Operations, effective immediately. This strategic leadership change is expected to impact the company’s operations and potentially strengthen its industry positioning.
The most recent analyst rating on (TNXP) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Tonix Pharma stock, see the TNXP Stock Forecast page.
Spark’s Take on TNXP Stock
According to Spark, TipRanks’ AI Analyst, TNXP is a Neutral.
Tonix Pharma’s stock score reflects a company in its growth phase with substantial revenue increases and strategic advancements in product development. However, significant challenges remain in profitability and cash flow sustainability, necessitating ongoing external funding. Positive corporate events provide some optimism, yet weak technical indicators and valuation concerns cap the overall score.
To see Spark’s full report on TNXP stock, click here.
On May 8, 2025, Tonix Pharma held its annual shareholder meeting where seven proposals were approved. Key decisions included the election of eight board members, ratification of EisnerAmper LLP as the accounting firm, and authorization for potential reverse stock splits. Additionally, shareholders approved amendments to the stock incentive plan, the 2025 Employee Stock Purchase Plan, and executive compensation, with a decision to hold executive compensation votes every three years.
Spark’s Take on TNXP Stock
According to Spark, TipRanks’ AI Analyst, TNXP is a Neutral.
Tonix Pharma’s stock score reflects a company in its growth phase with substantial revenue increases and strategic advancements in product development. However, significant challenges remain in profitability and cash flow sustainability, necessitating ongoing external funding. Positive corporate events provide some optimism, yet weak technical indicators and valuation concerns cap the overall score.
To see Spark’s full report on TNXP stock, click here.
On April 28, 2025, Tonix Pharmaceuticals presented promising data at the AACR Annual Meeting, demonstrating that their fusion protein mTFF2-MSA, combined with an anti-PD1 antibody, effectively activates cancer-killing CD8+ T Cells and reduces immunosuppression in tumor microenvironments in animal models. This development highlights Tonix’s potential impact in cancer treatment, particularly with their TNX-1700 candidate, which is in preclinical stages for gastric and colorectal cancers.
Spark’s Take on TNXP Stock
According to Spark, TipRanks’ AI Analyst, TNXP is a Neutral.
Tonix Pharma’s stock score reflects a growth phase with substantial revenue increases and strategic advancements in product development. However, the company faces significant profitability challenges and reliance on external funding, impacting financial sustainability. Positive corporate events provide some optimism, yet technical indicators remain weak, capping the overall score.
To see Spark’s full report on TNXP stock, click here.
On April 23, 2025, Tonix Pharmaceuticals presented promising preclinical data at the World Vaccine Congress in Washington. Their TNX-801 vaccine candidate showed efficacy in protecting animals against mpox and rabbitpox, including in immunocompromised subjects, indicating potential for future development and market opportunities.
Spark’s Take on TNXP Stock
According to Spark, TipRanks’ AI Analyst, TNXP is a Neutral.
Tonix Pharma’s strengths lie in its robust equity position and recent positive corporate events, including promising trial results and regulatory progress. However, ongoing profitability challenges and weak technical indicators weigh heavily on the stock score. The company’s growth phase and strategic advancements offer potential, but financial sustainability remains a concern.
To see Spark’s full report on TNXP stock, click here.
On March 24, 2025, Tonix Pharmaceuticals announced that the FDA will not require an Advisory Committee meeting for the New Drug Application of TNX-102 SL, a product candidate for fibromyalgia management. This development could streamline the approval process, potentially accelerating the product’s market entry and impacting the company’s operations and market positioning positively.
On March 10, 2025, Tonix Pharmaceuticals announced receiving a $50,000 grant from the Medical CBRN Defense Consortium to support the development of its TNX-801 vaccine candidate for mpox and smallpox. The grant will aid in creating a commercialization plan for TNX-801, which has shown promising results, including being significantly less virulent than traditional smallpox vaccines and providing durable protection in animal models.
On February 27, 2025, Tonix Pharma Limited, a subsidiary of Tonix Pharmaceuticals Holding Corp., signed an employment agreement with Siobhan Fogarty, the Chief Technical Officer. The agreement includes an annual salary, bonus eligibility, and equity compensation, with a 180-day notice period for termination, reflecting standard industry practices.
On March 3, 2025, Tonix Pharmaceuticals presented data at the 7th International Congress on Controversies in Fibromyalgia, highlighting the effectiveness of their transmucosal sublingual cyclobenzaprine (TNX-102 SL) in reducing pain associated with fibromyalgia through improved non-restorative sleep. This presentation underscores Tonix’s commitment to addressing fibromyalgia and strengthens its position in the pharmaceutical industry by showcasing successful results from two Phase 3 studies.